Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) FCF Margin (2023 - 2025)

Historic FCF Margin for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to 2340.4%.

  • CG Oncology's FCF Margin rose 346782100.0% to 2340.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 5387.67%, marking a year-over-year increase of 52440500.0%. This contributed to the annual value of 6931.26% for FY2024, which is 154604100.0% up from last year.
  • As of Q3 2025, CG Oncology's FCF Margin stood at 2340.4%, which was up 346782100.0% from 56376.92% recorded in Q1 2025.
  • CG Oncology's 5-year FCF Margin high stood at 2340.4% for Q3 2025, and its period low was 1464500.0% during Q4 2023.
  • For the 3-year period, CG Oncology's FCF Margin averaged around 191625.38%, with its median value being 14535.14% (2024).
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 2000000000bps in 2024, then tumbled by -514574500bps in 2025.
  • Over the past 3 years, CG Oncology's FCF Margin (Quarter) stood at 1464500.0% in 2023, then skyrocketed by 100bps to 4576.97% in 2024, then surged by 49bps to 2340.4% in 2025.
  • Its FCF Margin was 2340.4% in Q3 2025, compared to 56376.92% in Q1 2025 and 4576.97% in Q4 2024.